New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:20 EDTNPSP, HSP, AKRX, UTHR, MDVN, CBST, ALKS, SLXP, JAZZ, AUXLLeerink names top 10 acquisition candidates in biopharma
Leerink believes partnership and acquisition activity will remain a key feature of news flow and excess returns for investors in the biopharma industry during 2014 and into 2015. The firm's top 10 acquisition candidates in the space are: Alkermes (ALKS), Akorn (AKRX), Akorn (AUXL), Cubist (CBST), Hospira (HSP), Jazz Pharmaceuticals (JAZZ), Medivation (MDVN), NPS Pharmaceuticals (NPSP), Salix (SLXP) and United Therapeutics (UTHR).
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2015
07:10 EDTALKSAlkermes reports Q2 adjusted EPS (9c), consensus (10c)
Subscribe for More Information
July 29, 2015
17:05 EDTMDVNOn The Fly: Top stock stories for Wednesday
Stocks began the session in positive territory but soon turned mixed as the tech heavy Nasdaq was unable to hold its gains. The Federal Reserve's statement that accompanied its rate decision was little changed from its last meeting, keeping investors optimistic about a possible delay in its first interest rate hike in many years. ECONOMIC EVENTS: In the U.S., the Federal Reserve concluded a two-day meeting on monetary policy and kept benchmark interest rates unchanged between 0% and 0.25%, as expected. The Fed said information received since the last time the FOMC met indicates that economic activity has been expanding "moderately" in recent months, noting that the labor market continued to improve, with "solid job gains and declining unemployment." The central bank repeated that even after employment and inflation near "mandate-consistent levels," economic conditions may warrant keeping the target federal funds rate below "normal" levels. An index of pending home sales fell 1.8% in June, versus expectations for it to have risen 1% compared to the prior month. In China, the Shanghai composite index rose 3.4%, stemming its most recent stretch of declines, though the index is still deeply in the red on a week-to-date basis. COMPANY NEWS: Shares of Twitter (TWTR) fell $5.30, or 14.5%, to $31.24 after the company reported better than expected quarterly results but its management tempered expectations about its user growth. Several analysts cut their price targets on the stock and warned its shares may be range bound in the near-term, but maintained their buy ratings on the stock based on the social network operator's long-term potential. Analysts were not as ready to jump to the defense of another Internet stock, Yelp (YELP), which plunged $8.40, or 25.07%, to $25.11 after the local business review site operator reported lower than expected profit and lowered its fiscal year revenue guidance. At least eight research firms downgraded the stock after the company's outlook missed expectations and it announced the exit of brand advertising... Two defense contractors, Northrop Grumman (NOC) and General Dynamics (GD), advanced after each topped expectations with their quarterly reports and raised their fiscal year outlooks. General Dynamics shares gained 3.93% to $149.96 following its "beat and raise" report, while Northrop jumped 6.18% to $173.44. MAJOR MOVERS: Among the notable gainers was Cytec Industries (CYT), which gained 27.04% to $74.19 after agreeing to be acquired by Brussels-based Solvay (SVYZY) for $75.25 per share in cash, corresponding to an enterprise value of $6.4B. Among the noteworthy losers was Tableau Software (DATA), which fell $13.58, or 10.67%, to $113.64 after its earnings report. Cantor Fitzgerald analyst Brian White attributed today's pullback in shares to "very high" expectations going into the quarter, while Wedbush said Tableau's Q2 deceleration was due to difficulty in sustaining its "extraordinarily high" growth rate. Also lower were shares of Medivation (MDVN), which fell $8.77, or 8.39%, to $95.74 after Cowen analyst Eric Schmidt said prescription trends for the company's prostate cancer drug Xtandi have "slowed considerably." Schmidt, who thinks consensus expectations calling for Xtandi sales topping $3B in sales by 2019 are "far too high," recommended selling the shares and lowered his price target on the stock to $77. INDEXES: The Dow rose 121.12, or 0.69%, to 17,751.39, the Nasdaq gained 22.53, or 0.44%, to 5,111.73, and the S&P 500 advanced 15.32, or 0.73%, to 2,108.57.
15:52 EDTJAZZUSPTO review of Jazz patents negative but not unexpected, says BMO Capital
Subscribe for More Information
15:46 EDTJAZZJazz Pharmaceuticals says USPTO moving forward with review of Xyrem patents
Subscribe for More Information
15:08 EDTALKSNotable companies reporting before tomorrow's open
Subscribe for More Information
13:54 EDTALKSEarnings Watch: Alkermes up around 17% since last earnings report
Alkermes (ALKS) is scheduled to report second quarter earnings before the market open on Thursday, July 30 with a conference call scheduled for 8:30 am ET. Alkermes, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. EXPECTATIONS: Analysts are looking for a loss of (10c) per share on revenue of $142.8M, according to First Call. The consensus range for EPS is for a loss of (17c)-(4c) on revenue of $134.5M-$153.28M. LAST QUARTER: Alkermes reported first quarter EPS of 6c, compared to a consensus estimate of a loss of (3c), on revenue of $161.2M against estimates of $146.6M. The company reiterated all of its financial expectations for 2015 that it had previously given on March 9, when it cut its 2015 EPS view to (37c)-(50c) from (27c)-(40c). Q1 revenue from the company's anti-psychotic franchise, including Risperdal were $46.9M, compared to $49.6M for the same period in the prior year. Revenues from Amprya/Famprya were $36.5M, compared to $20.6M for the same period in the prior year. "Our results this quarter reflect strong revenues from our portfolio of key commercial products and focused investment in our promising late-stage pipeline of CNS product candidates that will drive our future growth," commented Alkermes CFO James Frates. Alkermes CEO Richard Pops noted that the company is on the "threshold" of its next growth phase and that Aripiprazole lauroxil, the company's long-acting atypical anti-psychotic for schizophrenia, is moving toward FDA approval and launch later this year. STREET RESEARCH: On June 26, Cowen said the clinical profile for Alkermes' ALKS 3831 continues to look interesting, as the firm's consultants believe data for the drug suggests a profile that would provide a significant benefit over Zyprexa for the treatment of schizophrenia. Cowen reiterated its Outperform rating and $80 price target on Alkermes shares. PRICE ACTION: Alkermes shares are up around 17% since the company's last earnings report on April 30, and are down almost 3% to $67.40 in midday trading ahead of Thursday's earnings release.
12:17 EDTMDVNMedivation plummets after Cowen highlights slowing Xtandi trends
Subscribe for More Information
12:04 EDTMDVNMedivation weakness a buying opportunity, says Barclays
Barclays said Medivation shares are pricing in a Q2 miss and lowered guidance, both of which is unlikely. The firm expects shares to react positively to US Xtandi sales numbers and reaffirmation of guidance, and recommends buying shares on weakness today.
07:39 EDTHSPHospira continues to see 'good momentum' across product lines
Subscribe for More Information
07:31 EDTHSPHospira reports Q2 adjusted EPS 85c, consensus 80c
Subscribe for More Information
July 28, 2015
06:08 EDTUTHRUnited Therapeutics reports Q2 EPS $2.55, consensus $2.31
Reports Q2 revenue $347.2M, consensus $360.41M.
July 27, 2015
10:40 EDTALKSLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
July 24, 2015
11:59 EDTJAZZLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry discusses the strengths and weaknesses of TEVA’s preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and the perspectives on recent updates in the Jazz Pharmaceuticals' Xyrem patent case on an Analyst/Industry conference call to be held on July 27 at 11 am.
July 21, 2015
10:01 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:54 EDTAKRXAkorn initiated with a Neutral at Susquehanna
Subscribe for More Information
July 20, 2015
10:26 EDTJAZZLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals / Generics Analyst Gerberry, along with MEDACorp Specialists Michael Belliveau, PhD and Shashank Upadhye, JD, discuss the strengths and weaknesses of TEVA's preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and perspectives on recent updates in the JAZZ Xyrem patent case on an Analyst/Industry conference call to be held on July 22 at 2 pm.
July 17, 2015
14:35 EDTALKSRecro Pharma entered into supply pact with Alkermes
Subscribe for More Information
08:38 EDTJAZZLeerink puts 25% odds on Teva, Mylan deal within 12 months
Subscribe for More Information
07:25 EDTAKRXAkorn risk/reward favorable into restatements, says JPMorgan
Subscribe for More Information
July 16, 2015
16:01 EDTHSPHospira announces U.S. launch of generic bivalirudin for injection
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use